Navigation Links
Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP

0 years of age, to 47.8% for those older than 60 years.(3)

"We are extremely encouraged by these PROMACTA results, and what this may mean for ITP patients," said Paolo Paoletti, M.D., Senior Vice President, Oncology Medicine Development Center, GSK. "This pivotal Phase III trial data and our ongoing efforts to assess the benefits of both short- and long-term treatment of PROMACTA will be part of GSK's commitment to work with regulatory authorities and ensure new treatment options for ITP patients are provided."

The Phase III trial was an international, randomized, double-blind, placebo-controlled study that enrolled 114 adults with chronic ITP and baseline platelet counts of <30,000/microliter. Eligible patients must have failed or stopped responding within three months of receiving one or more ITP therapies such as corticosteroids, immunoglobulins and/or splenectomy. Patients were allowed to continue on a concomitant ITP medication, provided their dose had been stable for at least a month prior to enrollment. These patients were randomized to either placebo (38 patients) or PROMACTA 50mg (76 patients) once daily for six weeks. The PROMACTA dose could be increased to 75mg in patients not responding after an initial three weeks of treatment. Patients were assessed for platelet count weekly and up to six weeks following treatment with PROMACTA. Bleeding events were assessed weekly using the World Health Organization (WHO) bleeding scale.(1)

At the end of the trial, 59% of PROMACTA treated patients and 16% of placebo treated patients achieved a platelet count of more than 50,000/microliter. Importantly, there was a significantly lower incidence of bleeding events during treatment with PROMACTA compared to placebo (p=0.029) with clinically significant bleeding (WHO Grades 2-4) observed in fewer PROMACTA patients (16%) than placebo patients (36%). The most common adverse event (AE) observed in this study was headache, reported in 8% and 11% of patien
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
11. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
Post Your Comments:
(Date:8/1/2014)... 2014  VanDeMark Chemical Inc., Lockport, ... phosgene and phosgene derivatives in North ... acquired Framochem Kft, a leading European-based manufacturer of ... . The purchase unites two companies ... the world,s largest, independent manufacturers of products based ...
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, ... (CFRI) today announced a partnership to expand awareness of ... through the CFChef Shares program. CFChef Shares will run ... of AbbVie,s CFChef program – an online resource for ... maintain a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... India , Aug. 1, 2014  Neuland ... providing active pharmaceutical ingredients (APIs), complex ... customers located in 85 countries, today announced financial ... (FY) 2015, ended June 30, 2014. ... by work flow re-prioritization to accommodate certain customer ...
Breaking Medicine Technology:VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
(Date:8/1/2014)... 2014 Market Publishers Ltd announces ... been added to its catalogue. , ... (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, ... drivers include, among others, increasing ageing population, rising ... 2015, the pharma market in India is anticipated ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... Patients with the progressive, deadly respiratory ailment known as ... to battle the disease, the U.S. Food and Drug ... new treatment, an inhaled spray called Striverdi Respimat (olodaterol) ... which is often linked to smoking, involves multiple lung ... Patients with COPD may experience a number of symptoms, ...
(Date:8/1/2014)... parents worry about their children choking on small objects or ... Such was the case for 15-month-old Landon Jones who started ... "At the time, Landon had a cold so it ... illness or choking," recalled his mother, Ula Jones. But, ... his windpipe and had to be removed via surgery. Landon ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2
... the National Academy of Sciences (IOM) in the US released ... calcium across all ages. The report is based on available ... role of these nutrients on bone health. Vitamin D deficiency ... been linked to the pathogenesis of osteoporosis and hip fractures ...
... (HealthDay News) -- A U.S. Food and Drug Administration advisory ... drugs for the prevention of prostate cancer, the third highest ... GlaxoSmithKline and Merck, respectively, are already approved to treat enlarged ... also lower the risk of prostate cancer by more than ...
... effect on our understanding of genetic biology and could usher ... review individual genome sequences to fully personalise medical treatment. ... for its $10m prize for the first privately funded company ... less than $10,000 per genome, the science writer Philip Ball ...
... Dec. 1 (HealthDay News) -- A test that measures the ... at an early stage and help doctors evaluate the effectiveness ... as early as possible -- before it destroys the optic ... the researchers, from the Bascom Palmer Eye Institute at the ...
... Reporter , TUESDAY, Nov. 30 (HealthDay News) -- Autistic children ... structure called the mitochondria, which is responsible for producing the ... defects may help to explain the onset or the severity ... the Dec. 1 issue of the Journal of the ...
... Academy of Otolaryngology Head and Neck Surgery (AAO-HNS), ... surgeons, has partnered with SAGE to publish its official ... in January 2011. A leading journal in the ... recent developments in treatment of the ear, nose, throat, ...
Cached Medicine News:Health News:IOF statement on new IOM dietary reference intakes for calcium and vitamin D 2Health News:FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer 2Health News:Physicists use graphene to decode DNA 2Health News:Cell Dysfunction May Play Part in Autism 2Health News:Cell Dysfunction May Play Part in Autism 3Health News:AAO-HNSF partners with SAGE to publish Otolaryngology-Head and Neck Surgery 2
... This remarkable anti-reflux valve ... plastic housing which prevents the ... closed when in sitting or ... virtually self-cleaning and interference free ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
Medicine Products: